Geniko Nosokomeio Nikaias Peiraia Ag. Panteleimon Geniko Nosokomeio Dytikis Attikis I
- Address
- Dimitrios Mantouvalos Str. 3, 184 54 Νikaia, Greece
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Therapeutics
The gastroenterology unit is exploring innovative therapeutic devices and integrated diagnostic‑therapeutic solutions across several disease groups, including cardiovascular, digestive, hormonal and immune disorders. Trials aim to assess safety and effectiveness of new treatment modalities while improving patient monitoring.
- Development of novel drug‑delivery platforms for inflammatory bowel disease
- Evaluation of advanced imaging techniques for hypertension assessment
- Assessment of therapeutic drug monitoring tools in immune‑mediated conditions
Geniko Nosokomeio Nikaias Peiraia hosts 18 active studies led by 10 investigators, fostering interdisciplinary collaboration.
Surgical Procedures – Operative
Research focuses on optimizing minimally invasive surgical approaches and peri‑procedural care for patients with gastrointestinal diseases. Studies evaluate bowel preparation regimens, endoscopic techniques, and operative management of disease complications.
- Optimization of second‑line colonoscopy preparation protocols
- Advancement of laparoscopic strategies for ulcerative colitis
- Surgical outcomes in Crohn’s disease complications
The department leverages its endoscopic expertise to enhance operative safety and patient recovery.
Cardiovascular Diseases
A suite of trials targets major cardiovascular risk factors such as hypertension, atherosclerotic disease and heart failure. Objectives include testing combination antihypertensives, novel agents for lipoprotein(a) reduction, and therapies aimed at preventing heart‑failure events.
- Fixed‑dose irbesartan/amlodipine for arterial hypertension
- Baxdrostat plus dapagliflozin to lower heart‑failure risk
- Zilebesiran impact on cardiovascular death and stroke
- Muvalaplin evaluation for elevated Lp(a) cardiovascular events
Ongoing investigations seek to reduce morbidity in patients with high cardiovascular risk.
Digestive System Diseases
The centre conducts extensive research on inflammatory bowel disease, addressing both Crohn’s disease and ulcerative colitis. Trials assess biologic agents, novel small molecules, and supportive therapies to achieve clinical remission and mucosal healing.
- Risankizumab maintenance therapy in ulcerative colitis
- Tulisokibart efficacy in moderate to severe Crohn’s disease
- Icotrokinra studies for ulcerative colitis remission
- MK‑7240 investigation for Crohn’s disease
- Evaluation of colonoscopy preparation effectiveness
With 18 active IBD studies, the department is a regional hub for advancing gastroenterology care.
Hormonal Diseases
Clinical investigations target endogenous Cushing’s syndrome and related metabolic disturbances. The focus is on therapies that mitigate hypercortisolemia‑induced hyperglycemia and improve endocrine control.
- Fluasterone buccal tablet for hyperglycemia in Cushing’s syndrome
- Assessment of metabolic outcomes after cortisol‑lowering interventions
- Biomarker studies for endocrine disorder monitoring
These efforts aim to enhance quality of life for patients with hormonal imbalances.
Immune System Diseases
Trials examine novel immunomodulatory therapies for conditions such as IgA nephropathy and broader immune‑mediated disorders. Long‑term safety and efficacy are central objectives.
- Long‑term safety evaluation of atacicept
- Immune modulation strategies in IgA nephropathy
- Investigations of immune response pathways in sepsis
The research program supports the development of targeted treatments for immune‑related diseases.
Pathological Conditions, Signs and Symptoms
Studies address acute conditions such as infection and sepsis, using early diagnostic markers to guide rapid therapeutic interventions. The goal is to improve survival through timely treatment decisions.
- PROMISE trial evaluating early meropenem guided by PSP levels
- Validation of qSOFA and NEWS2 scores for sepsis risk stratification
- Assessment of symptom‑based endpoints in critical care trials
Emphasis is placed on translating rapid diagnostic insights into actionable clinical care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Merck Sharp & Dohme LLC1active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Geniko Nosokomeio Nikaias Peiraia Ag. Panteleimon Geniko Nosokomeio Dytikis Attikis I
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tulisokibart | 3 | Unknown | 2024-08-20 | 2025-09-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.